The heparins and cancer

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Heparin and low molecular weight heparin are crucial for deep vein thrombosis (DVT) treatment and prevention, especially in malignancy.
• A significant link exists between malignant growth and heparin-like glycosaminoglycans (HLGAGs), supported by extensive research and dedicated journal issues.
• Previous reviews have detailed the historical evidence for the heparin-cancer connection from basic science to clinical trials.

Purpose of the Study:

• To provide an updated review of recent basic and clinical data on the heparin-cancer link.
• To elucidate the mechanisms by which HLGAGs regulate malignant cell behavior.
• To establish a theoretical foundation for testing HLGAGs in cancer patients.

Main Methods:

• Review of existing literature, including basic biochemistry, cell biology, animal models, and clinical trials.
• Analysis of recent data on HLGAGs' role in cancer.
• Synthesis of evidence regarding HLGAGs' impact on tumor cell growth, invasion, metastasis, angiogenesis, and matrix formation.

Main Results:

• HLGAGs regulate tumor cell growth via heparin-binding growth factors.
• Heparin-inhibitable enzyme systems control tumor cell invasion.
• Heparin-binding cell surface selectins influence tumor cell metastasis.
• HLGAGs play roles in tumor angiogenesis and matrix formation.
• HLGAGs may be a key factor in abnormal growth regulation in neoplasia.

Conclusions:

• HLGAGs offer a promising therapeutic target for cancer intervention.
• Targeted intervention of HLGAGs could address abnormal growth regulation in neoplasia.
• Further systematic testing of HLGAGs in cancer patients is warranted based on current evidence.